Novartis has signed a global licensing agreement with Legend Biotech to advance the latter’s chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including LB1102 for the treatment of extensive stage small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma. Through the deal, which includes a US$100 M upfront payment, Novartis plans to leverage its T-Charge™ platform to manufacture Legend’s cell therapies. This will mark the first time that Novartis applies its platform on cell therapy candidates that target solid tumours.